Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Decreases By 17.5%

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 64,583 shares, a decline of 17.5% from the December 15th total of 78,258 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average daily trading volume, of 64,617 shares, the short-interest ratio is currently 1.0 days. Based on an average daily trading volume, of 64,617 shares, the short-interest ratio is currently 1.0 days. Approximately 4.4% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, HC Wainwright lifted their target price on BiomX to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $26.00.

BiomX Price Performance

NYSEAMERICAN PHGE opened at $2.68 on Monday. BiomX has a 12 month low of $1.50 and a 12 month high of $22.06. The firm has a market capitalization of $4.10 million, a PE ratio of -0.11 and a beta of 1.60. The company’s 50 day simple moving average is $3.53 and its 200 day simple moving average is $7.44.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.